Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

被引：0
|
作者：
I Breitkreutz
M S Raab
S Vallet
T Hideshima
N Raje
C Mitsiades
D Chauhan
Y Okawa
N C Munshi
P G Richardson
K C Anderson
机构：
来源：
Leukemia | 2008年 / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Correction to: Leukemia (2008) 22, 1925–1932; doi:10.1038/leu.2008.174; published online 3 July 2008 Owing to a typesetting error, Figure 2b of the above article was published incorrectly. The correct figure is reproduced here. The publisher apologizes for this error and any inconvenience it may have caused.
引用
收藏
页码：1973 / 1973
相关论文
共 50 条
  • [11] Lenalidomide Related Diarrhea Correlates With Survival In Multiple Myeloma
    Faiman, Beth
    Sidana, Surbhi
    Elson, Paul
    Bruening, Kellie
    Duong, Hien K.
    Dean, Robert M.
    Valent, Jason
    Samaras, Christy
    Hastings, Debbie
    Smith, Mitchell R.
    Reu, Frederic J.
    BLOOD, 2013, 122 (21)
  • [12] A novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis
    Pandey, Manoj K.
    Gowda, Krishne
    Sung, Shen-shu
    Abraham, Thomas
    Budak-Alpdogan, Tulin
    Talamo, Giampolo
    Dovat, Sinisa
    Amin, Shantu
    EXPERIMENTAL HEMATOLOGY, 2017, 53 : 31 - 42
  • [13] Lenalidomide Inhibits the Multiple Myeloma Cell Survival Factor IRF4/MUM1
    Lopez-Girona, A.
    Mendy, D.
    Gaidarova, S.
    Brady, H.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S122 - S122
  • [14] Bone remodeling in patients with relapsed/refractory multiple myeloma who receive lenalidomide-based regimens.
    Terpos, Evangelos
    Christoulas, Dimitrios
    Kastritis, Efstathios
    Katodritou, Eirini
    Papanikolaou, Xenophon
    Roussou, Maria
    Stavropoulos, Nikolaos
    Tsionos, Konstantinos
    Pangalis, Gerassimos A.
    Zervas, Konstantinos
    Sezer, Orhan
    Dimopoulos, Meletios A.
    BLOOD, 2007, 110 (11) : 259B - 259B
  • [15] Mechanisms of Altered Bone Remodeling in Multiple Myeloma
    Brunetti G.
    Faienza M.F.
    Colaianni G.
    Grano M.
    Colucci S.
    Clinical Reviews in Bone and Mineral Metabolism, 2017, 15 (4): : 151 - 161
  • [16] Lenalidomide improves survival in previously treated patients with multiple myeloma
    不详
    ONCOLOGY-NEW YORK, 2006, 20 (01): : 43 - 43
  • [17] Erratum: Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
    D S Siegel
    P Richardson
    M Dimopoulos
    P Moreau
    C Mitsiades
    D Weber
    J Houp
    C Gause
    S Vuocolo
    J Eid
    T Graef
    K C Anderson
    Blood Cancer Journal, 2014, 4 : e202 - e202
  • [18] Erratum: Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
    Nikhil C Munshi
    Constantine Mitsiades
    Paul G Richardson
    Kenneth C Anderson
    Nature Clinical Practice Oncology, 2008, 5 : 493 - 493
  • [19] Lenalidomide inhibits the multiple myeloma cell-survival factor IRF4/MUM1
    Lopez-Girona, Antonia
    Mendy, Derek
    Brady, Helen
    Gaidarova, Svetlana
    CANCER RESEARCH, 2009, 69
  • [20] Biochemical bone markers in patients with multiple myeloma
    Nawawi, H
    Samson, D
    Apperley, J
    Girgis, SI
    JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 (10) : P11 - P11
12345